How to advise aspirin use in patients who need NSAIDs

Current Pharmaceutical Design

Volumn 13, Issue 22, 2007, Pages 2248-2260

  Sopena, F ^a   Lanas, Angel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Aspirin; Cardiovascular events; COX inhibitors; Coxib; Gastrointestinal events; Helicobacter pylori; Low dose aspirin; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LANSOPRAZOLE; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXICAM DERIVATIVE; PARECOXIB; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ADENOMATOUS POLYP; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPETITIVE INHIBITION; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; MONOTHERAPY; OPTIMAL DRUG DOSE; PAIN; PEPTIC ULCER; POSTOPERATIVE PAIN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SINGLE DRUG DOSE; THROMBOEMBOLISM; THROMBOSIS; ULCER; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATION; PAIN; RISK ASSESSMENT; RISK FACTORS;

EID: 34548266239     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781368837     Document Type: Review

References (100)

1. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 11: 521-35.
2. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
3. Sciulli MG, Capone ML, Tacconelli S, Patrignani P. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 2005; 57(suppl): 66-85.
4. Weaver AL. Review article: Aspirin, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-1 sparing agents. Aliment Pharmacol Ther (Symp Ser) 2005; 1: 2-5.
5. Lanas A, Rodrigo L, Marquez JL, Bajador E, Perez-Roldan F, Cabrol J, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003; 38: 693-700.
6. Lanas A. Economic analysis of strategies in the prevention of nonsteroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004; 20: 321-31.
7. Tannenbaum H, Peloso PM, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol 2000; 7 (supplA): 4A-16A.
8. Hunt RH, Barkun AN, Baron D, Bombardier C, Bursey FR, Marshall JR, et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents. Can J Gastroenterol 2002; 16: 231-240.
9. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004; 19: 197-208.
10. Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA. Canoar study Appropriateness of NSAID and Coxib Prescribing for Patients With Osteoarthritis by Primary Care Physicians in Ontario: Results From the CANOAR Study. Am J Manag Care 2004; 10: 742-750.
11. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
12. U.S. Preventive Services Task Force. Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale. Ann Intern Med 2002; 136: 157-60.
13. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002, 16: 1945-53.
14. Bates ER, Lau WC. Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation 2005; 111: 267-271.
15. Antithrombotic Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
16. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
17. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-13.
18. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, et al. A Randomized Trial of Low-dose aspirin in the Primary Prevention of Cardiovascular Disease in Women. N Engl J Med 2005; 352: 1293-304.
19. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation 2002; 106: 388-91.
20. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-72.
21. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. Un update on aspirin in the primary prevention of cardiovascular disease Arch Intern Med 2003; 163: 2006-10.
22. Sandler R S, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
23. Baron J.A, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
24. Terhaar Sive Droste JS, Tuynman JB, Van Dullemen HM, Mulder CJ. Chemoprevention for colon cancer: New opportunities, fact or fiction? Scand J Gastroenterol Suppl 2006; 243: 158-64.
25. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
26. Schnitzer TJ, Burmester GR, Myster E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004; 364: 665-74.
27. Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004; 164: 1243-6.
28. Goldstein JK, Huang B, Amer F, Christopoulos NG. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: Results of a post HOC subanalysis. Clin Ther 2004; 26: 1637-1643.
29. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99
30. Hawkey CJ, Lanas AI. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: A multidisciplinary expert statement. Am J Med 2001; 110 (1A): 79S-100S.
31. Hawkey CJ. Non-steroidal anti-inflammattory drug gastropathy: Causes and treatment. Scand J Gastroenterol Suppl 1996; 220: 124-7.
32. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: Increasing frequency of haemorrhage among older subjects. Gut 2002; 50: 460-4.
33. Perez-Aisa MA, Del Pino L, Siles M, Lanas A. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 21: 65-72.
34. Bruce B, Fries JF. The Arthritis, Rheumatism and Aging Medical Information System (ARAMIS): Still young at 30 years. Clin Exp Rheumatol 2005; 23 (5 Suppl 39): S163-7.
35. Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100: 1685-93.
36. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91.
37. Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: Overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52: 600-8.
38. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use. Pain 2000; 85: 169-82.
39. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
40. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-92
41. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387-437.
42. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2005; 325: 619-27.
43. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. PNAS 2002; 99: 13926-31.
44. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case. BMJ 2002; 324: 1287-8.
45. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. for the SUCCESS-I Investigators. Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study. Am J Med 2006; 119: 255-66.
46. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 1520-8.
47. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 2005; 331: 1310-6.
48. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez Perez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut Online First, published on May 10, 2006 as 10.1136/gut.2005.080754.
49. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anitiinflammatory drugs. N Engl J Med 1992; 327: 751-4.
50. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo Clin Gastroenterol Hepatol 2005; 3: 133-41.
51. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
52. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.
53. Nussmeier NA, Whelton AA, Brown MT. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
54. Curtis SP, Bockow B, Fisher C, Olaleye J, Compton A, Ko AT, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: A double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord 2005; 6: 58.
55. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080
56. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001; 98: 14583-8.
57. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
58. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 2002; 69 (Suppl 1): 40-46.
59. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control análisis. BMJ 2005; 330: 1366-73.
60. Howard PA, Patrice Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 2004; 43: 519-25.
61. Solomon DH, Schneeweiss S, Glynn RJ. Relationship between selective cyclooxygenase- 2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068-73.
62. Graham DJ, Campen D, Hui R. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective nonsteroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005; 365: 475-81.
63. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004; 364: 2021-9.
64. Dalen JE. Aspirin to Prevent Heart Attack and Stroke: What's the Right Dose? Am J Med 2006; 119: 198-202.
65. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219-26.
66. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218-24.
67. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801.
68. Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2003; 15: 173-178.
69. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long-term use of aspirin: Meta-analysis. BMJ 2000; 321: 1183-7.
70. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 862-869.
71. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997; 112: 683-689.
72. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-97.
73. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-839.
74. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 31: 827-30.
75. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 2004; 127: 395-402.
76. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32 (3 Suppl 1): 25-32.
77. Loll PJ, Picot D, Ekabo O, Garavito RM. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996; 35: 7330-40.
78. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
79. Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAID-induced gastropathy-COX selectivity and beyond. Br J Clin Pharmacol 2004; 58: 587-600.
80. Hawkey CJ, Gitton X, Hoexter G, Richard D, Weinstein WM. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. Clin Gastroenterol Hepatol 2006; 4: 57-66.
81. Scheiman JM. Gastroduodenal safety of cyclooxgenase-2 inhibitors. Curr Pharm Des 2003; 9: 2197-206.
82. Chan FKL, Ching JYL, Hung LCT, Wong VWS, Leung VKS, Kung NNS, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-44.
83. Ng FH, Wong SY, Chang CM, Chen WH, Kng C, Lanas-AI, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 443-9.
84. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, et al. Inhibition of clinical benifets of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191-5.
85. Livio M, Del Maschio A, Cerletti C, de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982; 23: 787-96.
86. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
87. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-8
88. Rahme E, Barkun A, Toubouti Y, Rochon S, LeLorier J. Do proton pump inhibitors infer additional gastrointestinal protection in patients given celecoxib? A retrospective cohort study. Gastroenterology 2005; 128 (Suppl 2): A864.
89. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73.
90. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002; 359: 14-22.
91. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411-8.
92. Jaspersen D, Koerner T, Schorr W, Brennenstuhl M, Raschka C, Hammar CH. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc 1995; 41: 5-7.
93. Rokkas T, Karameris A, Mavrogeorgis A. Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995, 41: 1-4
94. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increase the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16(4); 779-86
95. Chan FKL, Ching JYL, Suen BY, Wong VWS, Hung LCT, Hui, AJ; et al. Eradication of H. pylori for the prevention of recurrent ulcer bleeding in high-risk aspirin users: A 4-year Prospective Cohort Study. Gastroenterology 2005; 128 (Suppl 2); A133.
96. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
97. Vonkeman HE, Brouwers JRBJ, van der Laar MAFJ. Understanding the NSAID related risk of vascular events. BMJ 2006; 332: 895-8.
98. de Weck AL, Gamboa PM, Esparza R, Sanz ML. Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Curr Pharm Des 2006; 12(26): 3347-58.
99. Macchi L, Sorel N, Christiaens L. Aspirin resistance: Definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des 2006; 12(2): 251-8.
100. Salvi GE, Lang NP. The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. Curr Pharm Des 2005; 11 (14): 1757-69.